Susan Watkins
Family · Dallas, TXNPI 1750371316
Payments from drug & device makers
Across 274 payments — averaging $24.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Medtronic$1K
- AstraZeneca$716
- Dexcom, Inc.$447
- Novo Nordisk$341
- Boehringer Ingelheim$216
- plus $2K from 26 others
What the payments were for
- Travel & lodging$98114%
- Food & beverage$5,85686%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 47 | $1,425 |
| Medtronic | 13 | $1,374 |
| AstraZeneca | 32 | $716 |
| Dexcom, Inc. | 31 | $447 |
| Novo Nordisk | 21 | $341 |
| Boehringer Ingelheim | 10 | $216 |
| Xeris Pharmaceuticals, Inc. | 11 | $204 |
| Sanofi-aventis U.S. LLC | 11 | $201 |
| Corcept Therapeutics | 8 | $182 |
| Insulet Corporation | 8 | $181 |
| Amarin Pharma, Inc. | 11 | $180 |
| Amneal Pharmaceuticals LLC | 10 | $163 |
| Tandem Diabetes Care, Inc. | 4 | $157 |
| Mannkind Corporation | 9 | $150 |
| Novartis | 7 | $142 |
| Lilly USA, LLC | 8 | $140 |
| Ascensia Diabetes Care US Inc. | 5 | $117 |
| Merck | 6 | $82 |
| Sequel Med Tech, LLC | 2 | $64 |
| Amgen | 3 | $64 |
| Zealand Pharma US, Inc. | 3 | $55 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| BETA Bionics, Inc. | 2 | $34 |
| AbbVie | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Alvogen Inc | 1 | $14 |
| Cequr Corporation | 1 | $14 |
| BD | 1 | $13 |
| Nevro Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,837 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $129,677 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 42 | $62,192 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $28,087 |
| JardianceEmpagliflozin | 19 | $21,134 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $19,459 |
| FarxigaDapagliflozin Propanediol | 24 | $16,943 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $14,727 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $12,268 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,747 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $1,874 |
| Levothyroxine Sodium | 13 | $228 |
| Glimepiride | 21 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $341 | $129,67778 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $216 | $83,32761 claims |
| AstraZenecaFarxiga | $716 | $16,94324 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $201 | $12,26814 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $163 | $22813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Hayley McKessonDallas$165K
- Marcia HarrisDallas$156K
- Miles HortonDallas$72K
- Richard OrnbergDallas$56K
- Ifeoma OkekeDallas$48K
- Natasha SimmonsDallas$38K
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.